General

Impaired myocardial function occurs in 40-70% of dialysis patients. Previous research suggests that SGLT-2 inhibitors, such as dapagliflozin, may improve myocardial function in patients with severely impaired renal function. In 100 participants of the Renal Lifecycle trial treated with peritoneal dialysis (abdominal dialysis), we want to investigate whether dapagliflozin can improve heart muscle function. Improved myocardial function helps reduce the incidence of heart failure in dialysis patients. This additional study of heart muscle function is therefore called STOP Heart Failure in Peritoneal Dialysis, or STOP HF in PD.

To study whether dapagliflozin can improve heart muscle function, we will image the heart with an ultrasound and an MRI scan. In addition, we want to use a short questionnaire and a 6-minute walk test to measure whether dapagliflozin improves the condition of dialysis patients. Finally, by collecting outflow fluid, we want to investigate the effect of dapagliflozin on the peritoneum, as there is evidence that dapagliflozin can protect the peritoneum during peritoneal dialysis.

Participation

Patients receiving abdominal dialysis (peritoneal dialysis) at the start of the Renal Lifecycle trial can participate in these additional measurements of myocardial function.

Participation in the additional tests of myocardial function does not change the Renal Lifecycle trial study treatments and appointments. At the start of the study (draw appointment), after six months and after one year, additional measurements will be taken only during the Renal Lifecycle trial study appointment as shown below in the schedule.

The MRI of the heart will be done at the start of the study and after one year. The ultrasound of the heart, fitness measurements, collection of outflow fluid and an additional blood draw at study start and, after six months. If the participant is still being treated with peritoneal dialysis after one year, these examinations will also be repeated after one year.